FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Atkins

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Anatomy

Killer Cells, Natural

Co-author Network

Publications

TOP 3
Samuel J Klempner; Detlef Schuppan; Eric Yee; Toni K Choueiri; Leona A Doyle; Michael B Atkins
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
Eric Jonasch; William Y Kim; Ghada Kurban; Armin Pause; Michael B Atkins; Sean T Bailey; James Brugarolas; Ian J Davis; Judith Frydman; P Andrew Futreal; Amato J Giaccia; Brian I Rini; Pam Sharma; Cheryl L Walker; Amado J Zurita; W Kimryn Rathmell
State of the science: an update on renal cell carcinoma.
Daniel C Cho; Michael B Atkins
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Atkins (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Samuel J Klempner; Detlef Schuppan; Eric Yee; Toni K Choueiri; Leona A Doyle; Michael B Atkins
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(27):e264-8.
2012: Eric Jonasch; William Y Kim; Ghada Kurban; Armin Pause; Michael B Atkins; Sean T Bailey; James Brugarolas; Ian J Davis; Judith Frydman; P Andrew Futreal; Amato J Giaccia; Brian I Rini; Pam Sharma; Cheryl L Walker; Amado J Zurita; W Kimryn Rathmell
State of the science: an update on renal cell carcinoma.
Molecular cancer research : MCR 2012;10(7):859-80.
2012: Daniel C Cho; Michael B Atkins
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(11):2999-3001.
2011: Daniel C Cho; Michael B Atkins
Future directions in renal cell carcinoma: 2011 and beyond.
Hematology/oncology clinics of North America 2011;25(4):917-35.
2011: Erin R DeRose; Mee Young Lee; Alexander Pleet; Sharon Renzi; Virginia J Seery; Ryan J Sullivan; Wei Wang; Michael B Atkins
Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma.
Melanoma research 2011;21(4):364-9.
2011: R S Bhatt; D George; Michael B Atkins; A Norden-Zfoni; A O'Neill; Vikas P Sukhatme; P Y Wen; H K Wu; L Zhang; Amado J Zurita; John V Heymach
Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.
British journal of cancer 2011;105(1):112-7.
2011: Xiaoen Wang; Liang Zhang; David C Alsop; Michael B Atkins; Manoj Bhasin; Victoria Brown; S Nahum Goldberg; James W Mier; Sabina Signoretti; Rupal S Bhatt
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Journal of translational medicine 2011;9():220.
2011: Liang Zhang; Manoj Bhasin; Rachel Schor-Bardach; Xiaoen Wang; Michael P Collins; David Panka; Prabhakar Putheti; Sabina Signoretti; David C Alsop; Towia Libermann; Michael B Atkins; James W Mier; S Nahum Goldberg; Rupal S Bhatt
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
PloS one 2011;6(4):e19144.
2010: Amy Frankenthaler; Ryan J Sullivan; Wei Wang; Sharon Renzi; Virginia Seery; Mee-Young Lee; Michael B Atkins
Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma.
Melanoma research 2010;20(6):496-500.
2010: Rupal S Bhatt; Xiaoen Wang; Liang Zhang; Michael P Collins; Sabina Signoretti; David C Alsop; S Nahum Goldberg; Michael B Atkins; James W Mier
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.
Molecular cancer therapeutics 2010;9(10):2793-802.
2010: Ryan J Sullivan; Michael B Atkins
Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
Expert opinion on investigational drugs 2010;19(10):1205-16.
2010: Daniel C Cho; Matthew B Cohen; David J Panka; Michael Collins; Musie Ghebremichael; Michael B Atkins; Sabina Signoretti; James W Mier
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(14):3628-38.
2010: Ryan J Sullivan; Michael B Atkins
Cytokine therapy in melanoma.
Journal of cutaneous pathology 2010;37 Suppl 1():60-7.
2010: Rupal S Bhatt; Jaime Merchan; Robert Parker; Hua-Kang Wu; Liang Zhang; Virginia Seery; John V Heymach; Michael B Atkins; David McDermott; Vikas P Sukhatme
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Cancer 2010;116(7):1751-6.
2010: Andrea Bullock; David F McDermott; Michael B Atkins
Management of metastatic renal cell carcinoma in patients with poor prognosis.
Cancer management and research 2010;2():123-32.
2009: Gary R Hudes; Anna Berkenblit; Jay Feingold; Michael B Atkins; Brian I Rini; Janice Dutcher
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Seminars in oncology 2009;36 Suppl 3():S26-36.
2009: Toni K Choueiri; Michael B Atkins
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
Nature reviews. Clinical oncology 2009;6(12):679-80.
2009: Michael B Atkins; Uma Yasothan; Peter Kirkpatrick
Everolimus.
Nature reviews. Drug discovery 2009;8(7):535-6.
2009: Michael B Atkins; Toni K Choueiri; Daniel Cho; Meredith Regan; Sabina Signoretti
Treatment selection for patients with metastatic renal cell carcinoma.
Cancer 2009;115(10 Suppl):2327-33.
2009: Michael B Atkins; Ronald M Bukowski; Bernard J Escudier; Robert A Figlin; Gary H Hudes; William G Kaelin; W Marston Linehan; David F McDermott; James W Mier; Ivan Pedrosa; Brian I Rini; Sabina Signoretti; Jeffrey A Sosman; Bin Tean Teh; Christopher G Wood; Amado J Zurita; Laura King
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
Cancer 2009;115(10 Suppl):2247-51.
2009: Ryan J Sullivan; Michael B Atkins
Molecular-targeted therapy in malignant melanoma.
Expert review of anticancer therapy 2009;9(5):567-81.
2009: Daniel C Cho; Igor Puzanov; Meredith M Regan; Talya Schwarzberg; Virginia Seery; Mee-Young Lee; Vivian Liu; Rupal Bhatt; Henry B Koon; James W Mier; Jeffrey A Sosman; Michael B Atkins; David F McDermott
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009;32(2):181-5.
2009: Michael B Atkins
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy.
Medical oncology (Northwood, London, England) 2009;26 Suppl 1():18-22.
2008: Michael B Atkins; Jeffrey A Sosman; Sanjiv Agarwala; Theodore Logan; Joseph I Clark; Marc S Ernstoff; D H Lawson; Janice P Dutcher; Geoffrey Weiss; Brendan Curti; Kim A Margolin
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Cancer 2008;113(8):2139-45.
2008: Jeffrey A Sosman; Carole Carrillo; Walter J Urba; Lawrence E Flaherty; Michael B Atkins; JI Clark; Janet Dutcher; Kim A Margolin; James Mier; Jarod Gollob; John M Kirkwood; David J Panka; Nancy A Crosby; Kevin O'Boyle; Bonnie J Lafleur; Marc S Ernstoff
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2292-8.
2008: Edward L Korn; Ping-Yu Liu; Sandra J Lee; Judith-Anne W Chapman; Donna Niedzwiecki; Vera J Suman; James Moon; vernon sondak; Michael B Atkins; Elizabeth A Eisenhauer; Wendy R Parulekar; Svetomir N Markovic; Scott Saxman; John M Kirkwood
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):527-34.
2008: David J Panka; Daniel C Cho; Michael B Atkins; James W Mier
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines.
The Journal of biological chemistry 2008;283(2):726-32.
2007: Joseph I Clark; Jessica Mehrabi; Jeffrey A Sosman; Theodore F Logan; Kim Margolin; Janice P Dutcher; Walter J Urba; Marc S Ernstoff; David F McDermott; Ann M Lau; Michael B Atkins
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(8):839-46.
2007: David Avigan; Baldev Vasir; Daniel J George; William K Oh; Michael B Atkins; David F McDermott; Philip W Kantoff; Robert A Figlin; Michael J Vasconcelles; Yuanxin Xu; Donald Kufe; Ronald M Bukowski
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(7):749-61.
2007: David F McDermott; Michael B Atkins
More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3791-3.
2007: Hans J J van der Vliet; Henry B Koon; Michael B Atkins; Steven P Balk; Mark A Exley
Exploiting regulatory T-cell populations for the immunotherapy of cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(6):591-5.
2007: Michael B Atkins; David Carbone; George Coukos; Madhav V Dhodapkar; Marc S Ernstoff; James Finke; Thomas F Gajewski; Jared A Gollob; Michael T Lotze; Walter Storkus; Louis M Weiner
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(6):577-90.
2007: Antoine Hakimé; Andrew Hines-Peralta; Himaja Peddi; Michael B Atkins; Vikas P Sukhatme; Sabina Signoretti; Meredith Regan; S Nahum Goldberg
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
Radiology 2007;244(2):464-70.
2007: Kim Margolin; Michael B Atkins; Janice P Dutcher; Marc S Ernstoff; John W Smith; Joseph I Clark; Joseph Baar; Jeffrey A Sosman; Jeffrey Weber; Chetan Lathia; Janice Brunetti; Frank Cihon; Brian Schwartz
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3312-9.
2007: Malcolm S Mitchell; Judith Abrams; John A Thompson; Mohammed Kashani-Sabet; Ronald C DeConti; Wen-Jen Hwu; Michael B Atkins; Eric Whitman; Marc S Ernstoff; Frank G Haluska; James G Jakowatz; Tapas K Das Gupta; Jon M Richards; Wolfram E Samlowski; John J Costanzi; Frederick R Aronson; Albert B Deisseroth; Arkadiusz Z Dudek; Vicky E Jones
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2078-85.
2007: Michael B Atkins
The effect of recent drug approvals on translational research and drug development.
Clinical advances in hematology & oncology : H&O 2007;5(4):285-7.
2007: Diana C Gallagher; Rupal S Bhatt; Samir M Parikh; Parin Patel; Virginia Seery; David F McDermott; Michael B Atkins; Vikas P Sukhatme
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2115-20.
2007: Hans J J van der Vliet; Hans J J van der Vliet; Henry B Koon; Simon C Yue; Burak Uzunparmak; Virginia Seery; Marc A Gavin; Alexander Y Rudensky; Michael B Atkins; Steven P Balk; Mark A Exley
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2100-8.
2007: Jeffrey A Sosman; Igor Puzanov; Michael B Atkins
Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 2):764s-769s.
2007: Daniel Cho; Sabina Signoretti; Meredith Regan; James W Mier; Michael B Atkins
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 2):758s-763s.
2007: Michael B Atkins; Marc S Ernstoff; Robert A Figlin; Keith T Flaherty; Daniel J George; William G Kaelin; Eugene D Kwon; Towia Libermann; W Marston Linehan; David F McDermott; Augusto C Ochoa; Allan J Pantuck; Brian I Rini; Mark A Rosen; Jeffrey A Sosman; Vikas P Sukhatme; Johannes W Vieweg; Christopher G Wood; Laura King
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 2):667s-670s.
2007: Henry B Koon; Michael B Atkins
Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.
Expert review of anticancer therapy 2007;7(1):79-88.
2006: David F McDermott; Michael B Atkins
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
Seminars in oncology 2006;33(5):583-7.
2006: David F McDermott; Meredith M Regan; Michael B Atkins
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
Clinical genitourinary cancer 2006;5(2):114-9.
2006: Ken Wyman; Michael B Atkins; Victor Prieto; Omar Eton; David F McDermott; Francie Hubbard; Christine Byrnes; Kathleen Sanders; Jeffrey A Sosman
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Cancer 2006;106(9):2005-11.
2006: David J Panka; Michael B Atkins; James W Mier
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 2):2371s-2375s.
2006: Michael B Atkins; David E Elder; Richard Essner; Keith T Flaherty; Thomas F Gajewski; Frank G Haluska; Patrick Hwu; Ulrich Keilholz; John M Kirkwood; James W Mier; Merrick I Ross; Craig L Slingluff; vernon sondak; Jeffrey A Sosman; Martin A Weinstock; Laura King
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 2):2291s-2296s.
2006: David J Panka; Wei Wang; Michael B Atkins; James W Mier
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
Cancer research 2006;66(3):1611-9.
2005: Melissa P Upton; Robert A Parker; Amanda Youmans; David F McDermott; Michael B Atkins
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(5):488-95.
2005: Arnold H Zea; Paulo C Rodriguez; Michael B Atkins; Claudia Hernandez; Sabina Signoretti; Jovanny Zabaleta; David F McDermott; David G Quiceno; Amanda Youmans; Anne O'Neill; James W Mier; Augusto C Ochoa
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
Cancer research 2005;65(8):3044-8.
2005: David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffrey R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):133-41.
2004: Michael B Atkins; Meredith Regan; David F McDermott
Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 2):6342S-6S.
2004: Michael B Atkins; David Avigan; Ronald M Bukowski; Richard W Childs; Janice P Dutcher; Tim G Eisen; Robert A Figlin; James H Finke; Robert C Flanigan; Daniel J George; S Nahum Goldberg; Michael S Gordon; Othon Iliopoulos; William G Kaelin; W Marston Linehan; Allan Lipton; Robert J Motzer; Andrew C Novick; Walter M Stadler; Bin Tean Teh; James C Yang; Laura King
Innovations and challenges in renal cancer: consensus statement from the first international conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 2):6277S-81S.
2004: Hensin Tsao; Michael B Atkins; Arthur J Sober
Management of cutaneous melanoma.
The New England journal of medicine 2004;351(10):998-1012.
2004: David F McDermott; Michael B Atkins
Application of IL-2 and other cytokines in renal cancer.
Expert opinion on biological therapy 2004;4(4):455-68.
2004: Michael B Atkins; Manuel Hidalgo; Walter M Stadler; Theodore F Logan; Janice P Dutcher; Gary R Hudes; Young Park; Song-Heng Liou; Bonnie Marshall; Joseph P Boni; Gary Dukart; Matthew L Sherman
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):909-18.
2003: Joseph I Clark; Michael B Atkins; Walter J Urba; Steve Creech; Robert A Figlin; Janice P Dutcher; Lawrence E Flaherty; Jeffrey A Sosman; Theodore F Logan; Richard White; Geoffrey R Weiss; Bruce G Redman; Christopher P G Tretter; David F McDermott; John W Smith; Michael S Gordon; Kim Margolin
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3133-40.
2003: Jared A Gollob; Korina G Veenstra; Robert A Parker; James W Mier; David F McDermott; Daniel Clancy; Linda Tutin; Henry B Koon; Michael B Atkins
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2564-73.
2002: Michael B Atkins; Jared A Gollob; Jeffrey A Sosman; David F McDermott; Linda Tutin; Patricia Sorokin; Robert A Parker; James W Mier
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(10):3075-81.
2002: Paula G Fraenkel; Seward B Rutkove; Jean K Matheson; Mary Fowkes; Marie E Cannon; Mary-Elizabeth Patti; Michael B Atkins; Jared A Gollob
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(4):373-8.
2002: Michael B Atkins
Interleukin-2: clinical applications.
Seminars in oncology 2002;29(3 Suppl 7):12-7.
2002: Ulrich Keilholz; Jeffrey Weber; James H Finke; Dmitry I Gabrilovich; W Martin Kast; Mary L Disis; John M Kirkwood; Carmen Scheibenbogen; Jeff Schlom; Vernon C Maino; H Kim Lyerly; Peter P Lee; Walter Storkus; Franceso Marincola; Alexandra Worobec; Michael B Atkins
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(2):97-138.
2001: Jared A Gollob; M P Upton; W C DeWolf; Michael B Atkins
Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery.
Urology 2001;58(6):1058.
2001: C Curiel-Lewandrowski; Michael B Atkins
Immunotherapeutic approaches for the treatment of malignant melanoma.
Current opinion in investigational drugs (London, England : 2000) 2001;2(11):1553-63.
2001: Arthur Kaser; Gerald Brandacher; W Steurer; Susanne Kaser; Felix Offner; Heinz Zoller; Igor Theurl; W Widder; Clemens Molnar; Othmar Ludwiczek; Michael B Atkins; J W Mier; Herbert Tilg
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis.
Blood 2001;98(9):2720-5.
2001: Michael B Atkins; Bruce G Redman; James W Mier; Jared A Gollob; J Weber; Jeffrey A Sosman; B L MacPherson; T Plasse
A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):486-92.
2001: Kerry L Kilbridge; Jane C Weeks; Arthur J Sober; Frank G Haluska; Craig L Slingluff; Michael B Atkins; D E Sock; J M Kirkwood; Robert F Nease
Patient preferences for adjuvant interferon alfa-2b treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):812-23.
2001: Janice Dutcher; Michael B Atkins; Kim Margolin; G Weiss; J Clark; Jeffrey A Sosman; Theodore Logan; Frederick R Aronson; James W Mier
Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.
Medical oncology (Northwood, London, England) 2001;18(3):209-19.
2001: Michael B Atkins; Janice Dutcher; G Weiss; Kim Margolin; J Clark; Jeffrey A Sosman; Theodore Logan; Frederick R Aronson; James W Mier
Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
Medical oncology (Northwood, London, England) 2001;18(3):197-207.
2001: Jared A Gollob; James W Mier; Michael B Atkins
Clinical use of systemic IL-12 therapy.
Cancer chemotherapy and biological response modifiers 2001;19():353-69.
2001: Jared A Gollob; Korina G Veenstra; James W Mier; Michael B Atkins
Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(1):91-8.
2000: David F McDermott; James W Mier; D P Lawrence; Marcel R M van den Brink; MA Clancy; K M Rubin; Michael B Atkins
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2201-8.
2000: Jared A Gollob; James W Mier; Korina G Veenstra; David F McDermott; D Clancy; MA Clancy; Michael B Atkins
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1678-92.
2000: Michael B Atkins; L Kunkel; Mario Sznol; STEVEN ROSENBERG
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
The cancer journal from Scientific American 2000;6 Suppl 1():S11-4.
1999: Michael B Atkins; M T Lotze; Janice P Dutcher; Richard I Fisher; G Weiss; K Margolin; Jeffrey Abrams; Mario Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; STEVEN ROSENBERG
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2105-16.
1999: Edouard Vannier; Arthur Kaser; Michael B Atkins; Giamila Fantuzzi; Charles A Dinarello; J W Mier; Herbert Tilg
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
European cytokine network 1999;10(1):37-42.
1999: Howard Hochster; M H Strawderman; J E Harris; Michael B Atkins; Martin M Oken; R T Skeel; S J Jubelirer; D Parkinson
Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687).
Anti-cancer drugs 1999;10(2):245-8.
1999: Michael J Robertson; C Cameron; Michael B Atkins; Michael S Gordon; M T Lotze; Matthew L Sherman; Jerome Ritz
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):9-16.
1998: Michael B Atkins
Immunotherapy and experimental approaches for metastatic melanoma.
Hematology/oncology clinics of North America 1998;12(4):877-902, viii.
1998: David F McDermott; E G Trehu; James W Mier; D Sorce; W Rand; L Ronayne; K Kappler; MA Clancy; M Klempner; Michael B Atkins
A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1203-13.
1997: John P Leonard; Matthew L Sherman; G L Fisher; L J Buchanan; G Larsen; Michael B Atkins; Jeffrey A Sosman; Janice P Dutcher; N J Vogelzang; J L Ryan
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
Blood 1997;90(7):2541-8.
1997: Michael B Atkins; Michael J Robertson; Michael S Gordon; M T Lotze; M DeCoste; J S DuBois; Jerome Ritz; Alan B Sandler; H D Edington; P D Garzone; James W Mier; C M Canning; L Battiato; H Tahara; Matthew L Sherman
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):409-17.
1997: Michael B Atkins
The treatment of metastatic melanoma with chemotherapy and biologics.
Current opinion in oncology 1997;9(2):205-13.
1997: J S Du Bois; E G Trehu; James W Mier; L Shapiro; M Epstein; M Klempner; C Dinarello; K Kappler; L Ronayne; W Rand; Michael B Atkins
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1052-62.
1997: Jeffrey A Sosman; Frederick R Aronson; Mario Sznol; Michael B Atkins; Janice P Dutcher; Geoffrey R Weiss; R E Isaacs; Kim Margolin; Richard I Fisher; M L Ernest; James W Mier; L Oleksowicz; J R Eckhardt; D Levitt; James Doroshow
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):39-46.
1996: E G Trehu; James W Mier; J S Dubois; D Sorce; M S Klempner; M Epstein; C A Dinarello; L Shapiro; K Kappler; L Ronayne; Michael B Atkins
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(8):1341-51.
1995: Michael B Atkins; K Kappler; James W Mier; R E Isaacs; E M Berkman
Interleukin-6-associated anemia: determination of the underlying mechanism.
Blood 1995;86(4):1288-91.
1995: J S Du Bois; J E Udelson; Michael B Atkins
Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(2):119-23.
1995: G R Weiss; Kim Margolin; Mario Sznol; Michael B Atkins; L Oleksowicz; R Isaacs; Jeffrey A Sosman; James Doroshow; E G Trehu; Janice P Dutcher
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(1):52-6.
1994: Joseph A Sparano; Richard I Fisher; G R Weiss; Kim Margolin; Frederick R Aronson; M J Hawkins; Michael B Atkins; Janice P Dutcher; E R Gaynor; D H Boldt
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):216-23.
1994: Michael B Atkins; K R O'Boyle; Jeffrey A Sosman; G R Weiss; Kim Margolin; M L Ernest; K Kappler; James W Mier; Joseph A Sparano; Richard I Fisher
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(8):1553-60.
1994: Herbert Tilg; L Shapiro; E Vannier; D D Poutsiaka; E Trehu; Michael B Atkins; Charles A Dinarello; James W Mier
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(6):3189-98.
1994: Herbert Tilg; E Trehu; L Shapiro; D Pape; Michael B Atkins; Charles A Dinarello; James W Mier
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans.
Cytokine 1994;6(2):215-9.
1994: Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; Rasim Gucalp; Richard I Fisher; M Sunderland; James Doroshow; M L Ernest; James W Mier
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(2):147-53.
1994: Herbert Tilg; E Trehu; Michael B Atkins; Charles A Dinarello; James W Mier
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.
Blood 1994;83(1):113-8.
1994: M J Hawkins; Michael B Atkins; Janice P Dutcher; Richard I Fisher; G R Weiss; Kim Margolin; A A Rayner; Mario Sznol; D R Parkinson; Elisabeth Paietta
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(1):74-8.
1993: E G Trehu; J M Isner; James W Mier; D D Karp; Michael B Atkins
Possible myocardial toxicity associated with interleukin-4 therapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(4):348-51.
1993: Joseph A Sparano; Richard I Fisher; M Sunderland; Kim Margolin; M L Ernest; Mario Sznol; Michael B Atkins; Janice P Dutcher; K C Micetich; G R Weiss
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1969-77.
1993: H Tilg; L Shapiro; Michael B Atkins; C A Dinarello; James W Mier
Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(6):3299-307.
1993: Herbert Tilg; D Pape; E Trehu; L Shapiro; Michael B Atkins; Charles A Dinarello; James W Mier
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy.
Journal of immunological methods 1993;163(2):253-8.
1993: Jeffrey A Sosman; G R Weiss; Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; K O'Boyle; Richard I Fisher; D H Boldt; James Doroshow
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1496-505.
1993: Joseph A Sparano; Lawrence J Brandt; J P Dutcher; J S DuBois; Michael B Atkins
Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2.
Annals of internal medicine 1993;118(8):617-8.
1993: Michael B Atkins; Joseph A Sparano; Richard I Fisher; G R Weiss; Kim Margolin; K I Fink; L Rubinstein; A Louie; James W Mier; Rasim Gucalp
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):661-70.
1992: Michael B Atkins; G Vachino; Herbert Tilg; D D Karp; N J Robert; K Kappler; James W Mier
Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1802-9.
1992: E M Massarotti; N Y Liu; J Mier; Michael B Atkins
Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy.
The American journal of medicine 1992;92(6):693-7.
1992: N P Sauter; Michael B Atkins; J W Mier; R M Lechan
Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report.
The American journal of medicine 1992;92(4):441-4.
1992: G R Weiss; Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; Janice P Dutcher; E R Gaynor; D H Boldt; James Doroshow; M H Bar
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):275-81.
1991: G Vachino; Jeffrey A Gelfand; Michael B Atkins; J D Tamerius; P Demchak; James W Mier
Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.
Blood 1991;78(10):2505-13.
1991: P A Demchak; James W Mier; N J Robert; K O'Brien; J A Gould; Michael B Atkins
Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(10):1821-30.
1991: Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; N Ciobanu; Richard I Fisher; G R Weiss; James Doroshow; M H Bar; M J Hawkins
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(3):214-20.
1990: Mario Sznol; James W Mier; Joseph A Sparano; E R Gaynor; G R Weiss; Kim Margolin; M H Bar; M J Hawkins; Michael B Atkins; Janice P Dutcher
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.
Journal of biological response modifiers 1990;9(6):529-37.
1990: James W Mier; G Vachino; Mark S Klempner; Frederick R Aronson; R Noring; S Smith; Eugene Brandon; W Laird; Michael B Atkins
Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.
Blood 1990;76(10):1933-40.
1990: M H Bar; Mario Sznol; Michael B Atkins; N Ciobanu; K C Micetich; D H Boldt; Kim Margolin; Frederick R Aronson; A A Rayner; M J Hawkins
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1138-47.
1990: Mark S Klempner; R Noring; James W Mier; Michael B Atkins
An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy.
The New England journal of medicine 1990;322(14):959-65.
1990: David R Snydman; B Sullivan; M Gill; J A Gould; D R Parkinson; Michael B Atkins
Nosocomial sepsis associated with interleukin-2.
Annals of internal medicine 1990;112(2):102-7.
1989: T Ryan; Michael B Atkins; J W Mier; E M Berkman
Lymphokine-activated killer cell generation and recovery. Comparison of an automated cell processing device and a manual procedure.
Transfusion 1989;29(6):491-5.
1989: Mario Sznol; Janice P Dutcher; Michael B Atkins; A R Rayner; Kim Margolin; E R Gaynor; G R Weiss; Frederick R Aronson; D R Parkinson; M J Hawkins
Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.
Cancer treatment reviews 1989;16 Suppl A():29-38.
1989: Kim Margolin; A A Rayner; M J Hawkins; Michael B Atkins; Janice P Dutcher; Richard I Fisher; G R Weiss; James Doroshow; HS Jaffe; M Roper
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):486-98.
1988: James W Mier; G Vachino; J W van der Meer; R P Numerof; S Adams; Joseph Cannon; H A Bernheim; Michael B Atkins; D R Parkinson; Charles A Dinarello
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.
Journal of clinical immunology 1988;8(6):426-36.
1988: Michael B Atkins; James W Mier; D R Parkinson; J A Gould; E M Berkman; Marshall M Kaplan
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.
The New England journal of medicine 1988;318(24):1557-63.
1988: James W Mier; Frederick R Aronson; R P Numerof; G Vachino; Michael B Atkins
Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
Pathology and immunopathology research 1988;7(6):459-76.
1986: M Allegretta; Michael B Atkins; R A Dempsey; E C Bradley; M W Konrad; A Childs; S N Wolfe; James W Mier
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2).
Journal of clinical immunology 1986;6(6):481-90.
1986: Michael B Atkins; J A Gould; M Allegretta; J J Li; R A Dempsey; R A Rudders; D R Parkinson; S Reichlin; James W Mier
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(9):1380-91.